RBRichard H. Beigi

Richard H. Beigi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Richard H. Beigi has a total of 76 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Key steps forward for maternal immunization: Policy making in action

    by R.H. Beigi, S.B. Omer, K.M. Thompson


  • Implementation of a prospective pregnancy registry for antiretroviral based HIV prevention trials

    by Felix G. Mhlanga, Lisa Noguchi, Jennifer E. Balkus, Samuel Kabwigu, Rachel Scheckter, Jeanna Piper, Heather Watts, Colin O’rOurke, Kristine Torjesen, Elizabeth R. Brown, et al.

    Background: Safety data on pregnancy and fetal outcomes among women in HIV prevention trials are urgently needed to inform use of effective antiretroviral agents for HIV prevention. We describe an effective, efficient, and novel method to prospectively collect perinatal safety data concurrent with on-going parent clinical trials. Methods: The Microbicide Trials Network (MTN)-016 study is a multinational prospective pregnancy exposure registry designed to capture pregnancy and neonatal outcomes. Studies currently contributing data to this registry included phase I and II safety trials with planned exposures to candidate HIV prevention agents, as well as phase IIB and III efficacy trials capturing data on pregnancy and infant outcomes following inadvertent fetal exposure during study participation. Results: To date, participants from two phase I studies and two effectiveness trials have participated in MTN-016, resulting in 420 pregnant women and 381 infants enrolled. Infant retention has been high, with 329 of 381 (86%) infants completing the 12-month follow-up visit. Conclusion: In a research setting context, it is feasible to establish and implement a prospective, multinational HIV chemoprophylaxis pregnancy registry that will generate pregnancy exposure data in a robust fashion.


  • Treatment of infections during pregnancy: Progress and challenges

    by Lisa M. Noguchi, Richard H. Beigi

    Emergence of Zika virus as a pathogen with important implications for perinatal outcomes highlights the need to identify safe and effective strategies for prevention and treatment of maternal infections. While substantial progress has been made in this area in recent years, significant regulatory and health systems barriers must still be overcome to identify and deliver evidence-based drug therapies for pregnant women. We review progress and outstanding challenges associated with the identification and implementation of new treatment options for maternal infections. We describe several strategies in use to optimize the application of existing evidence.Birth Defects Research 109:387–390, 2017.


  • Open Access

    A randomized safety and pharmacokinetic trial of daily tenofovir 1% gel in term and near‐term pregnancy

    by Richard H Beigi, Lisa M Noguchi, Elizabeth Montgomery, Joseph Biggio, Craig W Hendrix, Mark A Marzinke, James Y Dai, Jason Pan, Ratiya Kunjara Na Ayudhya, Jill L Schwartz, et al.

    Introduction: Vaginal tenofovir (TFV) 1% gel may reduce incident HIV‐1 and herpes simplex virus 2 infection. Pregnancy may increase risk of HIV acquisition, and incident HIV in pregnancy potentiates perinatal HIV transmission. Our objective was to investigate the safety and pharmacokinetics of seven days of TFV 1% vaginal gel in term and near‐term pregnancy.Methods: Ninety‐eight healthy pregnant women, stratified to a term cohort followed by a near‐term cohort, were enrolled into a 2:1 randomized, double‐blinded, placebo‐controlled trial. Women received TFV or placebo gel for seven consecutive days with pharmacokinetic sampling on days 0 and 6. Maternal and cord blood were collected at delivery. Primary end points included laboratory and genital adverse events, adverse pregnancy and neonatal outcomes, and maternal TFV levels.Results: Most adverse events were grade 1 and none of the grade 3 or 4 adverse events were related to study product. There was no significant difference in safety end points between the two pregnancy cohorts (p=0.18); therefore, their data were combined. Primary safety end point rates were similar for mothers randomized to the TFV gel vs placebo arm (72.7 and 68.8%, p=0.81). The same was true for newborns in the TFV gel vs placebo arms (4.5% vs 6.3%, p=0.66). All women randomized to TFV had quantifiable serum levels within eight hours of dosing, with low overall median (interquartile range) day 0 and day 6 peak values (3.8 (2.0 to 7.0) and 5.8 (2.6 to 9.4) ng/mL, respectively).Conclusions: Daily TFV 1% vaginal gel use in term and near‐term pregnancy appears to be safe and produces low serum drug levels.


    • 26 November 2015
      • Vol. 60, 378-82

    Text Messaging to Improve Preventive Health Attitudes and Behaviors During Pregnancy: A Prospective Cohort Analysis.

    by Michelle H Moniz, Leslie A Meyn, Richard H Beigi

    To delineate the effects of text messages sent to pregnant women to promote preventive health beliefs and behaviors. A prospective cohort analysis was performed among women who participated in a randomized, controlled trial aimed at improving preventive health. Participants (158 pregnant women enrolled from 2010-2012) received 12 weekly text messages encouraging preventive health behaviors (tobacco cessation, condom use for disease prevention, nutrition optimization, seat belt use, breastfeeding). Pre- and postintervention surveys assessed preventive health beliefs and practices. At follow-up, participants agreed that receiving text messages changed their beliefs about targeted preventive health behaviors: smoking (50%), sexually transmitted disease prevention (72%), prenatal vitamins (83%), seat belt use (68%), nutritious foods (84%), and breastfeeding (68%). Many participants reported more frequent engagement in target behaviors at follow-up than at baseline: decreased tobacco use (among 41% of smokers), more consistent condom use (among 7% of sexually active participants), more prenatal vitamin intake (32%), more frequent seatbelt use (32%), more frequent healthy food intake (41%), and intention to breastfeed longer (21%). Pregnant women receiving text messages promoting preventive health reported improvements in targeted beliefs and behaviors, suggesting that text messaging may be used for health promotion during pregnancy.


  • Oseltamivir for influenza in pregnancy

    by Richard H. Beigi, Raman Venkataramanan, Steve N. Caritis


    • 21 September 2013
      • Vol. 58, 383-8

    Perceptions and acceptance of immunization during pregnancy.

    by Michelle H Moniz, Wendy S Vitek, Aletha Akers, Leslie A Meyn, Richard H Beigi

    To estimate patients' perceptions of the need, safety and acceptability of vaccination during pregnancy. An office-based survey was offered to patients presenting for obstetric and gynecologic care from December 2007 to July 2008 at an academic women's hospital. The anonymous questionnaire assessed demographics, medical and vaccination history, interest in receiving vaccines, and beliefs about vaccination safety. Data were evaluated using descriptive statistics and chi2 analyses. A total of 1,436 completed surveys were available for analysis, including 573 from pregnant women. Pregnant women were less likely than non-pregnant women to report perceived risks from vaccine-preventable illness (22.8% vs. 34.5%, p < 0.001) and to believe that their doctor thinks they should get vaccines (42.6% vs. 49.7%, p < 0.027). Nearly two-thirds (61%) reported concern about possible vaccine effects on their pregnancy. However, the overwhelming majority (89%) of pregnant women surveyed reported willingness to accept vaccination during pregnancy if recommended by their obstetrician. Despite concerns about vaccine safety and a low perceived need for immunization, most pregnant respondents endorse acceptance of vaccination when recommended by their obstetrician. These findings suggest that obstetric providers should maximize opportunities for uptake of appropriate immunizations during pregnancy.


  • Performing Drug Safety Research During Pregnancy and Lactation: Biomedical HIV Prevention Research as a Template

    by Richard H. Beigi, Lisa Noguchi, Gina Brown, Jeanna Piper, D. Heather Watts

    Evidence-based guidance regarding use of nearly all pharmaceuticals by pregnant and lactating women is limited. Models for performing research may assist in filling these knowledge gaps. Internationally, reproductive age women are at high risk of human immunodeficiency virus (HIV) acquisition. Susceptibility to HIV infection may be increased during pregnancy, and risk of maternal-child transmission is increased with incident HIV infection during pregnancy and lactation. A multidisciplinary meeting of experts was convened at the United States National Institutes of Health to consider paradigms for drug research in pregnancy and lactation applicable to HIV prevention. This report summarizes the meeting proceedings and describes a framework for research on candidate HIV prevention agent use during pregnancy and lactation that may also have broader applications to other pharmaceutical products.